DNMT1 and nasopharyngeal carcinoma: miR-152 inhibited the proliferation, migration, or invasion by targeting the DNMT1 3′UTR directly in hepatitis B virus-related hepatocellular carcinoma [28], ovarian cancer [29], glioma [30], nasopharyngeal cancer [31] and bladder cancer cells [32].